Dr Reddys Laboratories Stock Current Valuation
| RDY Stock | USD 70.91 0.40 0.56% |
Valuation analysis of Dr Reddys Laboratories helps investors to measure Dr Reddys' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. Enterprise Value is likely to rise to about 740.6 B in 2024, whereas Enterprise Value Over EBITDA is likely to drop 7.87 in 2024. Fundamental drivers impacting Dr Reddys' valuation include:
Price Book 3.7037 | Enterprise Value -40.8 B | Enterprise Value Ebitda 0.1358 | Price Sales 0.0448 | Forward PE 19.5313 |
Fairly Valued
Today
Please note that Dr Reddys' price fluctuation is very steady at this time. Calculation of the real value of Dr Reddys Laboratories is based on 3 months time horizon. Increasing Dr Reddys' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Dr Reddys Laboratories is useful when determining the fair value of the RDY stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Dr Reddys. Since Dr Reddys is currently traded on the exchange, buyers and sellers on that exchange determine the market value of RDY Stock. However, Dr Reddys' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 70.91 | Real 71.15 | Target 70.11 | Hype 70.87 |
The real value of RDY Stock, also known as its intrinsic value, is the underlying worth of Dr Reddys Laboratories Company, which is reflected in its stock price. It is based on Dr Reddys' financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of Dr Reddys' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Dr Reddys' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Dr Reddys Laboratories helps investors to forecast how RDY stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Dr Reddys more accurately as focusing exclusively on Dr Reddys' fundamentals will not take into account other important factors: Dr Reddys Laboratories Company Current Valuation Analysis
Dr Reddys' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Dr Reddys Current Valuation | (40.82 B) |
Most of Dr Reddys' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Dr Reddys Laboratories is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
RDY Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Dr Reddys is extremely important. It helps to project a fair market value of RDY Stock properly, considering its historical fundamentals such as Current Valuation. Since Dr Reddys' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Dr Reddys' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Dr Reddys' interrelated accounts and indicators.
Click cells to compare fundamentals
RDY Current Valuation Historical Pattern
Today, most investors in Dr Reddys Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Dr Reddys' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Dr Reddys current valuation as a starting point in their analysis.
Dr Reddys Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Dr Reddys Laboratories has a Current Valuation of (40.82 Billion). This is 384.23% lower than that of the Pharmaceuticals sector and significantly lower than that of the Health Care industry. The current valuation for all United States stocks is significantly higher than that of the company.
RDY Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Dr Reddys' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Dr Reddys could also be used in its relative valuation, which is a method of valuing Dr Reddys by comparing valuation metrics of similar companies.Dr Reddys is currently under evaluation in current valuation category among related companies.
Dr Reddys Current Valuation Drivers
We derive many important indicators used in calculating different scores of Dr Reddys from analyzing Dr Reddys' financial statements. These drivers represent accounts that assess Dr Reddys' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Dr Reddys' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 511.9B | 746.6B | 702.3B | 776.0B | 698.4B | 733.4B | |
| Enterprise Value | 531.9B | 762.0B | 721.2B | 783.7B | 705.4B | 740.6B |
RDY Fundamentals
| Return On Equity | 0.21 | ||||
| Return On Asset | 0.12 | ||||
| Profit Margin | 0.19 % | ||||
| Operating Margin | 0.25 % | ||||
| Current Valuation | (40.82 B) | ||||
| Shares Outstanding | 166.52 M | ||||
| Shares Owned By Institutions | 15.03 % | ||||
| Number Of Shares Shorted | 625.76 K | ||||
| Price To Earning | 31.58 X | ||||
| Price To Book | 3.70 X | ||||
| Price To Sales | 0.04 X | ||||
| Revenue | 245.88 B | ||||
| Gross Profit | 113.84 B | ||||
| EBITDA | 108.78 B | ||||
| Net Income | 60.48 B | ||||
| Cash And Equivalents | 2.93 B | ||||
| Cash Per Share | 208.58 X | ||||
| Total Debt | 13.47 B | ||||
| Debt To Equity | 0.12 % | ||||
| Current Ratio | 1.98 X | ||||
| Book Value Per Share | 1,609 X | ||||
| Cash Flow From Operations | 58.87 B | ||||
| Short Ratio | 3.51 X | ||||
| Earnings Per Share | 3.75 X | ||||
| Price To Earnings To Growth | 4.71 X | ||||
| Target Price | 78.03 | ||||
| Number Of Employees | 25.86 K | ||||
| Beta | 0.34 | ||||
| Market Capitalization | 12 B | ||||
| Total Asset | 322.85 B | ||||
| Retained Earnings | 215.59 B | ||||
| Working Capital | 118.53 B | ||||
| Current Asset | 1.81 B | ||||
| Current Liabilities | 976 M | ||||
| Annual Yield | 0.01 % | ||||
| Five Year Return | 0.72 % | ||||
| Net Asset | 322.85 B | ||||
| Last Dividend Paid | 40.0 |
About Dr Reddys Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Dr Reddys Laboratories's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Dr Reddys using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Dr Reddys Laboratories based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Dr Reddys Laboratories offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dr Reddys' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dr Reddys Laboratories Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dr Reddys Laboratories Stock:Check out Dr Reddys Piotroski F Score and Dr Reddys Altman Z Score analysis. Note that the Dr Reddys Laboratories information on this page should be used as a complementary analysis to other Dr Reddys' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Complementary Tools for RDY Stock analysis
When running Dr Reddys' price analysis, check to measure Dr Reddys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dr Reddys is operating at the current time. Most of Dr Reddys' value examination focuses on studying past and present price action to predict the probability of Dr Reddys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dr Reddys' price. Additionally, you may evaluate how the addition of Dr Reddys to your portfolios can decrease your overall portfolio volatility.
| Stocks Directory Find actively traded stocks across global markets | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |
Is Dr Reddys' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dr Reddys. If investors know RDY will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dr Reddys listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.103 | Dividend Share 40 | Earnings Share 3.75 | Revenue Per Share 272.4618 | Quarterly Revenue Growth 0.066 |
The market value of Dr Reddys Laboratories is measured differently than its book value, which is the value of RDY that is recorded on the company's balance sheet. Investors also form their own opinion of Dr Reddys' value that differs from its market value or its book value, called intrinsic value, which is Dr Reddys' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dr Reddys' market value can be influenced by many factors that don't directly affect Dr Reddys' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dr Reddys' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dr Reddys is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dr Reddys' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.